• April 21, 2024

FDA Expert Panel Votes In Favor Of Johnson & Johnson COVID-19 Vaccine : Coronavirus Updates : NPR

A health care worker took a dose of Johnson & Johnson’s COVID-19 vaccine from a vial at Klerksdorp Hospital in Klerksdorp, South Africa on Feb. 18. Phill Magakoe / AFP via Getty Images hide the caption

Toggle labeling

Phill Magakoe / AFP via Getty Images

A health care worker withdrew a dose of Johnson & Johnson’s COVID-19 vaccine from a vial at Klerksdorp Hospital in Klerksdorp, South Africa, on February 18.

Phill Magakoe / AFP via Getty Images

In a unanimous 22-0, an advisory panel recommended the Food and Drug Administration to approve the COVID-19 vaccine developed by Johnson & Johnson for emergency use in adults during the pandemic.

The vote for the vaccine, which requires only one shot to protect, was made to answer this question: Do the benefits of the Johnson & Johnson vaccine outweigh the risks for use in people aged 18 and over?

The FDA usually follows the advice of its professional advisor. If the agency agrees, the Johnson & Johnson vaccine would be the third approved for use in the United States

A quick decision is expected given the state of the pandemic. The FDA approved the Pfizer-BioNTech and Moderna COVID-19 vaccines a day after the same panel recommended them for release in separate meetings last December.

The Johnson & Johnson vaccine was tested in an international study on approximately 40,000 people, half of whom received the vaccine and half of whom received a placebo. The study found that the company’s vaccine was 66% overall effective at preventing moderate to severe COVID-19 illnesses. For a disease judged to be severe or critical, the effectiveness was 85%. The study was carried out in the United States, South America, and South Africa.

The main study included in the company’s application found that the Johnson & Johnson vaccine prevented hospitalizations and deaths related to COVID-19 for 28 days or more after immunization.

Overall efficacy scores are below 95% for Pfizer for COVID-19 disease prevention and 94% for Moderna.

With the outbreak of the pandemic, the coronavirus mutated. Variants first observed in South Africa and Brazil, where the Johnson & Johnson vaccine was tested, mutated in a way that helps them evade the immune response triggered by vaccines developed against the original form of the virus .

Of more than 6,000 study participants surveyed within a week of vaccination, the most common side effects were injection site pain (49%), headache (39%), fatigue (38%), and muscle pain (33%). . These side effects were mostly mild or moderate.

Approval of Johnson & Johnson’s vaccine would help expand the range of COVID-19 shots available. The company said 4 million doses of vaccine would be available in the US once the FDA gives its OK. A total of 20 million cans are expected to be ready by the end of March, and Johnson & Johnson is committed to delivering 100 million cans by the end of June under its contract with the federal government.


Read Previous

Joe Biden’s Mixed Iran Messages

Read Next

Deshaun Watson News

Leave a Reply

Your email address will not be published. Required fields are marked *